171 related articles for article (PubMed ID: 31808943)
1. Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
Garcia Spezza E; Brethon B; Petit A; Mazingue F; Gandemer V; Boissel N; Carausu L; Reguerre Y; Leverger G; Ducassou S
Br J Haematol; 2020 Jan; 188(1):170-173. PubMed ID: 31808943
[No Abstract] [Full Text] [Related]
2. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.
Strocchio L; Gurnari C; Santoro N; Putti MC; Micalizzi C; Zecca M; Cuccurullo R; Girardi K; Diverio D; Testi AM; Lo-Coco F; Locatelli F
Br J Haematol; 2019 Apr; 185(2):360-363. PubMed ID: 30028005
[No Abstract] [Full Text] [Related]
3. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.
Shah G; Mikhail FM; Bachiasvili K; Vachhani P; Erba HP; Papadantonakis N
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):143-146. PubMed ID: 31629725
[TBL] [Abstract][Full Text] [Related]
5. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
Zheng H; Jiang H; Hu S; Liao N; Shen D; Tian X; Hao G; Jin R; Li J; Fang Y; Ju X; Liu A; Wang N; Zhai X; Zhu J; Hu Q; Li L; Liu W; Sun L; Wang L; Dai Y; Feng X; Li F; Liang H; Luo X; Yan M; Yin Q; Chen Y; Han Y; Qu L; Tao Y; Gao H; He Z; Lin L; Luo J; Pan K; Zhang J; Zhang R; Zhou M; Zhang Y; Wang L; Zhang R; Xiao P; Ling Y; Peng X; Peng Y; Wang T;
J Clin Oncol; 2021 Oct; 39(28):3161-3170. PubMed ID: 34077242
[TBL] [Abstract][Full Text] [Related]
6. Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.
Breccia M; Vignetti M; Annibali O; Cottone F; Luppi M; Borlenghi E; Rodeghiero F; Efficace F
Br J Haematol; 2020 Sep; 190(5):e304-e307. PubMed ID: 32557531
[No Abstract] [Full Text] [Related]
7. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
Lou Y; Tong H; Yu W; Wei J; Xu W; Mao L; Jin J
Leuk Res; 2019 Aug; 83():106168. PubMed ID: 31202077
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
Min GJ; Cho BS; Park SS; Park S; Jeon YW; Yahng SA; Shin SH; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ
Ann Hematol; 2020 May; 99(5):973-982. PubMed ID: 32270215
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
11. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
Gill H; Yim R; Lee HKK; Mak V; Lin SY; Kho B; Yip SF; Lau JSM; Li W; Ip HW; Hwang YY; Chan TSY; Tse E; Au WY; Kumana CR; Kwong YL
Cancer; 2018 Jun; 124(11):2316-2326. PubMed ID: 29579321
[TBL] [Abstract][Full Text] [Related]
14. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
16. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.
Stahl M; Tallman MS
Leuk Lymphoma; 2019 Dec; 60(13):3107-3115. PubMed ID: 31842650
[TBL] [Abstract][Full Text] [Related]
17. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia.
Tsumura Y; Yamada Y; Osumi T; Kato M; Terashima K; Shioda Y; Kiyotani C; Matsumoto K; Tomizawa D
J Pediatr Hematol Oncol; 2020 May; 42(4):322-325. PubMed ID: 30807394
[TBL] [Abstract][Full Text] [Related]
19. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
Gill H; Kumana CR; Yim R; Hwang YY; Chan TSY; Yip SF; Lee HKK; Mak V; Lau JSM; Chan CC; Kho B; Wong RSM; Li W; Lin SY; Lau CK; Ip HW; Leung RYY; Lam CCK; Kwong YL
Cancer; 2019 Sep; 125(17):3001-3012. PubMed ID: 31090936
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid.
Breccia M; Molica M; Efficace F; Minotti C; Latagliata R; Foà R; Lo Coco F
Br J Haematol; 2014 Nov; 167(3):428-30. PubMed ID: 24957334
[No Abstract] [Full Text] [Related]
[Next] [New Search]